286-300 of 813
Breastfeeding with MS: Monoclonal Antibodies May Not Impact Child Development
NeuroFrontiersBreastfeeding with MS: Monoclonal Antibodies May Not Impact Child Development
Exploring the Clinical Treatments of Schizophrenia
NeuroFrontiersExploring the Clinical Treatments of Schizophrenia
Ashley Baker, MSN, PMHNP
Nabil Ali, MD
The Role of Occupational Therapy in Schizophrenia Management
NeuroFrontiersThe Role of Occupational Therapy in Schizophrenia Management
Ashley Baker, MSN, PMHNP
Lauren Walker, OT
Investigating the Prevalence of Comorbidities in MS Clinical Trials
NeuroFrontiersInvestigating the Prevalence of Comorbidities in MS Clinical Trials
Ashley Baker, MSN, PMHNP
Amber Salter, PhD
Disparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
NeuroFrontiersDisparities in DMT Access: Women with MS Are Less Likely to Receive Treatment
Andrew Wilner, MD, FACP, FAAN
Victoria Leavitt, PhD
Assessing Disability in MS Patients with the SNRS and CombiWISE Tools
NeuroFrontiersAssessing Disability in MS Patients with the SNRS and CombiWISE Tools
Andrew Wilner, MD, FACP, FAAN
Dejan Jakimovski, MD, PhD
- advertisement
The Alarming Shortage of ADHD Medication and Its Implications on Patients
NeuroFrontiersThe Alarming Shortage of ADHD Medication and Its Implications on Patients
Understanding the Cellular Basis for Altered Cognition in Schizophrenia
NeuroFrontiersUnderstanding the Cellular Basis for Altered Cognition in Schizophrenia
Ashley Baker, MSN, PMHNP
Samuel Dienel, PhD
Practices for Preventing Polypharmacy in Multiple Sclerosis
NeuroFrontiersPractices for Preventing Polypharmacy in Multiple Sclerosis
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Ahmed Z. Obeidat, MD, PhD
Lauren Beranek, BS
From Assessment to Management: Tackling Catatonia in Schizophrenic Patients
NeuroFrontiersFrom Assessment to Management: Tackling Catatonia in Schizophrenic Patients
Ashley Baker, MSN, PMHNP
Stanley N. Caroff, MD
How Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
NeuroFrontiersHow Alzheimer's and Lewy Body Pathology Impact CAA Risk Factors
Charles Turck, PharmD, BCPS, BCCCP
Jagan Pillai, MD, PhD
Advancements in Multiple Sclerosis: Insights from the 2024 ACTRIMS Forum
NeuroFrontiersAdvancements in Multiple Sclerosis: Insights from the 2024 ACTRIMS Forum
- advertisement
Exploring the Latest in MS Cognitive Rehabilitation Strategies
NeuroFrontiersExploring the Latest in MS Cognitive Rehabilitation Strategies
Nancy Chiaravalloti, PhD
Visionary Insights: Assessing MS-Related Retinal Changes with Adaptive Optics
NeuroFrontiersVisionary Insights: Assessing MS-Related Retinal Changes with Adaptive Optics
Daniel Harrison, MD
Family Planning Clinical Considerations for Patients with Multiple Sclerosis
NeuroFrontiersFamily Planning Clinical Considerations for Patients with Multiple Sclerosis
Ashley Baker, MSN, PMHNP
Anna A. Shah, MD
